Aescap

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.

Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.

i-Optics is a medical device company based in The Hague, Netherlands, specializing in advanced corneal diagnostic solutions. Founded in 2006, it focuses on empowering cataract surgeons by providing a comprehensive suite of examinations necessary for toric, multifocal, and extended depth of focus intraocular lens implantation. Its technology includes corneal topography, posterior corneal analysis, mesopic and photopic pupillometry, and full-color photography, all designed to enhance the understanding of corneal properties. By employing innovative techniques such as ray tracing and a unique LED positioning system, i-Optics aims to improve surgical outcomes and increase the volume of premium patient care.

Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.

Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.

Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

i-Optics is a medical device company based in The Hague, Netherlands, specializing in advanced corneal diagnostic solutions. Founded in 2006, it focuses on empowering cataract surgeons by providing a comprehensive suite of examinations necessary for toric, multifocal, and extended depth of focus intraocular lens implantation. Its technology includes corneal topography, posterior corneal analysis, mesopic and photopic pupillometry, and full-color photography, all designed to enhance the understanding of corneal properties. By employing innovative techniques such as ray tracing and a unique LED positioning system, i-Optics aims to improve surgical outcomes and increase the volume of premium patient care.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

Affectis Pharmaceuticals is a company focused on developing innovative drugs aimed at treating neurodegenerative and neuroinflammatory diseases. The firm specializes in discovering and advancing therapies for psychiatric and inflammatory disorders, drawing on research related to conditions such as depression and schizophrenia. By leveraging scientific insights, Affectis seeks to address unmet medical needs in these challenging areas of healthcare.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.

Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.

Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.

Affectis Pharmaceuticals is a company focused on developing innovative drugs aimed at treating neurodegenerative and neuroinflammatory diseases. The firm specializes in discovering and advancing therapies for psychiatric and inflammatory disorders, drawing on research related to conditions such as depression and schizophrenia. By leveraging scientific insights, Affectis seeks to address unmet medical needs in these challenging areas of healthcare.